Skip to main content

Global Enterprises to Acquire Majority Stake in Predictive Therapeutics

NEW YORK(GenomeWeb) – Global Enterprises Group today said that it has reached a deal to acquire a majority stake in molecular diagnostics and therapeutics firm Predictive Therapeutics for an undisclosed amount. 

The deal is anticipated to be completed in 10 days, after which changes to Predictive's management and board will be announced, Global said. 

Predictive was organized to develop, commercialize, acquire, and invest in molecular diagnostic technologies, as well as therapeutic products, with plans to commercialize novel therapeutics developed through the use of gene-based companion diagnostics. 

Global is a diversified holding company based inVirginia Beach, Va.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.